R Squared’s Caribou Biosciences CRBU Stock Holding History

R Squared’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,268	Closed	-$28.6K	–	561
2025 Q3	$28.6K	Buy	+12,268	New	+$23.2K	0.01%	521

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

R Squared's CRBU Position: Q4 2025 in Review

R Squared sold out of Caribou Biosciences (CRBU) in Q4 2025, closing a stake of 12,268 shares — an estimated $28.6K sold.

R Squared first reported a position in CRBU in Q3 2025 and held it in 1 quarter. The position peaked at $28.6K in Q3 2025. 124 funds tracked by Wall St. Rank hold CRBU as of Q4 2025.

R Squared reported no remaining Caribou Biosciences position as of Q4 2025 after selling out during the quarter.
R Squared sold 12,268 Caribou Biosciences shares in Q4 2025, an estimated $28.6K.
R Squared first reported a position in Caribou Biosciences in Q3 2025 and held it in 1 quarter.
R Squared's Caribou Biosciences position peaked at $28.6K in Q3 2025.
124 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2025.

Based on R Squared's 13F filing for Q4 2025, filed 30 Jan 2026.